AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02634333 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
Study NCT02634333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferred aflibercept
Description: Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
Study NCT01094678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX™ Stent
Description: Stenting of the superfemoropopliteal artery.
Study NCT00415129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza virus
Description: 0.5mL, Intramuscular
Study NCT02170610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS
Study NCT02170610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Study NCT03913949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2575
Description: Multiple dose cohorts, PO, every day (QD) of a 28-day cycle
Study NCT01004367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Environmental- and individual based components carried out in the school.
Study NCT01016184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Oral vitamin D 100,000 IU
Study NCT02438228 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac output measurement
Description: Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
Study NCT00670228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine (LANTUS)
Description: Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
Study NCT00670228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine (Apidra)
Description: Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.~Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL.
Study NCT00670228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Standard insulin therapy titrated to blood sugar control
Study NCT02757079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-15
Description: NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
Study NCT03156010 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neuro Kinetics IPAS
Description: Testing with PAS device
Study NCT03156010 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Oculogica EyeBox
Description: Testing with Oculogica EyeBox device
Study NCT01016184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04113746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better asthma self-management and incorporation of physical activity
Description: Participants in the asthma and exercise lifestyle change arm will participate in 4 sessions focused on behavioral change and goal-setting education to teach them how to better incorporate exercise into their daily lives and better manage their asthma. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
Study NCT04113746 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Asthma Education
Description: General asthma education, but no discussion of the role of exercise and other lifestyle habits in asthma self-management. Following sessions 1 and 4, these participants will use the accelerometer to track activity, but will be blinded to the data.
Study NCT03156010 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SyncThink EyeSync Device
Description: Testing with SyncThink EyeSync device
Study NCT01072149 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00376935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Keratinocyte growth factor administered via injection
Study NCT03438890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Warm saline
Description: In subjects allocated to the warm saline group, a thermos flask, which was filled with heated sterile water, was used. A 1000 ml bottle of sterile water was heated to 60 ˚C in a stove for an hour at minimum. Just before introducing into the abdominal cavity, the laparoscope was placed into the thermos flask for 30 seconds at minimum . After each incidence of laparoscopic lens fogging (LLF), the scope was briefly inserted into the thermos flask about 10 seconds, and was then wrapped gauze around the lens before abdominal reinsertion.
Study NCT03438890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-fog agent
Description: In the anti-fog agent group, Ultra-Stop TM (Sigmaphrarm, Vienna, Austria), which is a commercial anti-fogging solution containing alcohol, surfactant, and water for medical optical devices, was used. Wiping the lens with gauze soaked in Ultra-Stop TM and allowing the surfactant to act for 5 seconds, the laparoscope was introduced into the abdominal cavity. After each laparoscopic lens fogging (LLF), the scope was removed from the abdomen and cleaned using the same corresponding method.
Study NCT03438890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: In the chlorhexidine group, the lens was wiped with gauze soaked in 4% chlorhexidine detergent solution (Firson, Cheonan, Korea) for 5 seconds before introducing into the abdominal cavity, and chlorhexidine was reapplied on the lens at the occurrence of laparoscopic lens fogging (LLF).
Study NCT02171481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate polymorph II
Study NCT02171481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate polymorph I
Study NCT02805530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First line systemic treatment
Description: Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
Study NCT02805530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical treatment
Description: to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
Study NCT02805530 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients will receive dose and fraction regimen according to the metastatic site.
Study NCT02805530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
Study NCT01469065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
Study NCT01469065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
Study NCT01469065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04991532
Description: Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
Study NCT01469065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-0499132
Description: Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
Study NCT00376935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Palifermin placebo
Description: Keratinocyte growth factor placebo administered via injection
Study NCT01469065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
Study NCT01282593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Impact of CD9 expression level on motility assays
Description: 1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.~Adhesion results will be validated on patient samples of B-ALL.
Study NCT01282593 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Post-transcriptional regulation of CD9
Description: 2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.~Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples.
Study NCT01583010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ANV(R)
Description: Device: Advanced Needle Visualization Technology ®~Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.~Arms: ANV ® Group
Study NCT02016963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Raxibacumab
Description: Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
Study NCT00915798 — intervention group
Intervention type: BEHAVIORAL
Intervention: Cigarette smoking
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
Study NCT00915798 — intervention group
Intervention type: BEHAVIORAL
Intervention: Abstinence
Description: Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
Study NCT03438968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Cardiac Rehabilitation exercise training
Study NCT03438968 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Cardiac Rehabilitation exercise training
Study NCT01873352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: catheter ablation
Description: Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
Study NCT01873352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: renal sympathetic denervation
Description: Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
Study NCT01588288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Galectin 3 dosage
Description: Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
Study NCT02554071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist - Smoking Cessation Support
Description: Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
Study NCT04324424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMS5552
Description: single dose of HMS5552 25mg
Study NCT03499639 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
Description: * Patients with eGFR between 59-30ml/min: a co-formula of ombitasvir (OBV; 25mg)/ paritaprevir (PTV; 150mg)/ ritonavir (r; 100mg) (OBV/PTV/r) once-daily plus ribavirin (RIB) was given for 12 weeks. Dose adjustment of RIB was made as follow: If eGFR was 30-59 ml/min, an alternating dosing of 200 mg and 400 mg daily; if eGFR 15-30 ml/min, dosing was 200 mg once daily.~* Patients on hemodialysis: a co-formula of OBV/PTV/r (25/150/100mg) once-daily plus RIB 200 mg 3 times/week, only in the days that they have their hemodialysis settings, 4 hours before the hemodialysis setting for 12 weeks.
Study NCT00743925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varespladib Methyl (A-002)
Description: 2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
Study NCT00743925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varespladib Methyl (A-002)
Description: 2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
Study NCT00071110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: For subjects randomized to EA, needles were placed at points GV-20-on the crown of the head and yin tang-on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
Study NCT00071110 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
Study NCT04522440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: to relieve the pain of inpatients in the hospice Ward
Description: This study will use pain scale, distress thermometer and POMS to understand whether the patient's pain status have changed.
Study NCT02695446 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Minocycline
Description: Oral extended release minocycline
Study NCT03919656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
Study NCT03919656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Study NCT01268462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox+PEP
Description: For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
Study NCT01268462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen+PEP
Description: For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
Study NCT01268462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliox
Description: For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
Study NCT03337373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Description: A single dose of 0.2 mg/kg intravenous bolus cisatracurium will be administered and blood samples will be taken before and at least 7 occasions post dose (at 1, 5, 10, 12, 15, 20, 30, and/or 60 minutes after a single bolus).
Study NCT01940731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium
Description: 3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
Study NCT01016925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tunnelized perineural catheter
Description: the catheter will be tunneled 2-3 cm subcutaneously.
Study NCT02220621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinked hyaluronic acid gel
Description: After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
Study NCT02220621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foleys balloon catheter
Description: After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
Study NCT02220621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foleys balloon catheter
Description: After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
Study NCT03751852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Coaching
Description: 28 classes in 16 weeks
Study NCT03751852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 28 classes in 16 weeks
Study NCT01112969 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based supportive coaching OSCAR
Description: The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
Study NCT01112969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list control group (TAU)
Description: Waiting-list control group (treatment as usual, TAU, no specific intervention)